Ask AI
ProCE Banner Activity

CE

Optimizing BTK Inhibitor Therapy in CLL: Updates and Strategies for Oncology Pharmacists

Video

In this certified on-demand webcast, expert faculty discuss the management of chronic lymphocytic leukemia (CLL) with currently approved BTK inhibitors, including how to monitor and mitigate treatment-related adverse events, based on evidence from key clinical trials.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: June 04, 2025

Expiration: December 03, 2025

Continue Activity

Share

Provided by

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

ProCE Banner
ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly

Target Audience

This activity is intended for oncology/hematology pharmacists and other clinical practice stakeholders caring for patients with CLL.

Program Learning Goal

This activity aims to improve learners’ knowledge, confidence, and competence in the individualization of BTKi therapy in patients with CLL, including treatment selection and AE management.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Differentiate covalent and noncovalent BTK inhibitors according to selectivity, binding, efficacy and AE profiles​

  • Integrate guideline recommendations, current evidence, prognostic information and staging, and patient factors and preferences to the selection of first-line BTK inhibitor therapy for CLL​

  • Formulate individualized treatment plans for the selection and sequencing of BTK inhibitor therapy in relapsed/refractory CLL based on factors including intolerance to prior therapy, duration of remission, and presence of resistance mutations​

  • Use evidence-based strategies to monitor and manage AEs and address challenges to adherence and access to treatments in CLL

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

James Davis, PharmD, BCOP: consultant/advisor/speaker: Bristol Myers Squibb, Janssen.

Victoria Nachar, PharmD, BCOP: consultant/advisor/speaker: BeiGene, Genmab, GlaxoSmithKline.

The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 04, 2025, through December 03, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

CE Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-25-008-H01-P has been assigned to this home study application-based activity. This activity is approved for 1 contact hour (0.10 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.